Abbott Laboratories (ABT) said Monday that its Coronary Intravascular Lithotripsy System has received an investigational device exemption from the US Food and Drug Administration.
The company said its intravascular lithotripsy clinical trial, which aims to improve outcomes in coronary artery disease patients, will enroll up to 335 people in 47 locations in the US.
The investigational device aims to treat arterial calcium blockages by using high-energy sound pressure waves, the company said.
Price: 127.09, Change: +0.74, Percent Change: +0.59
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.